ESR1 and breast cancer: These results collectively suggest that the sensitivity of breast cancer cells, with either endogenous ERα expression (i.e., MCF-7) or transfection of ERα (i.e., MDA-MB-231/wtERα), to AFP464 remains unaltered regardless whether ERα is liganded or not.